par SARTORIUS STED BIO (EPA:DIM)
Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA
Aubagne, January 1, 2023
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on December 31st 2022:
As a reminder, the following resources appeared on the last half year statement on 30 June 2022 on the liquidity account:
The following resources appeared on the liquidity account when the activity started:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a total solutions provider, the company helps its customers to manufacture biotech medications safely, rapidly and economically. Headquartered in Aubagne, France, the shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. With its own manufacturing and R&D sites in Europe, North America and Asia and an international network of sales companies, Sartorius Stedim Biotech has a global reach. The Group has been annually growing by double digits on average and has been regularly expanding its portfolio by acquisitions of complementary technologies. In 2021, the company employed more than 10,400 people, and earned sales revenue of around 2.89 billion euros.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 Petra.mueller2@sartorius.com
Sartorius Stedim Biotech S.A. Z.I. Les Paluds Avenue de Jouques, CS 91051 13781 Aubagne Cedex, France Phone: +33.(0)4.42.84.56.00 Fax: +33.(0)4.42.84.56.19 www.sartorius.com
|